Bucharest

• A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre … Recruiting
  2025-524366-21-00 5 2026-04-29 treatment-naive Chronic Lymphocytic Leukemia
• A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use … Recruiting
  2025-524157-13-00 1 2026-04-28 Chronic Hepatitis B
• A study for adolescents who are depressed and thinking of suicide Recruiting
  2024-518615-19-00 5 2026-04-22 Major Depressive Disorder
• A study to test the effects and safety of palopegteriparatide in adolescents with long-term hypoparathyroidism Recruiting
  2025-523928-52-00 5 2026-04-22 Chronic hypoparathyroidism
• Testing HLX43 in Advanced Lung Cancer (Non-Small Cell): A Global Safety and Effectiveness Study Recruiting
  2025-523803-31-00 4 2026-04-16 Advanced non-small cell lung cancer (NSCLC)
• Dose-finding study of LAD603 in adults with alopecia areata Recruiting
  2025-523342-27-00 4 2026-04-10 Alopecia areata
• A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting
  2025-522191-86-00 5 2026-04-02 Focal segmental glomerulosclerosis
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• A study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A … Recruiting
  2025-521858-42-00 5 2026-03-16 Hemophilia
• A study to assess the efficacy and safety of empasiprubart in adults with CIDP Recruiting
  2025-520805-10-00 5 2026-03-12 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus. Recruiting
  2025-522729-36-00 7 2026-03-11 Chronic Hepatitis Delta.
• A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting
  2024-513911-28-00 10 2026-03-04 Acute Ischemic Stroke
• A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Bipol … Recruiting
  2025-521845-26-00 5 2026-03-02 BP-I mania or mania with mixed features
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Recruiting
  2025-523202-32-00 5 2026-02-26 Major Depressive Disorder
• A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini … Recruiting
  2025-521558-40-00 5 2026-02-12 Pulmonary Hypertension Associated with Interstitial Lung Disease
• A Multi-Stage Study to Test a New Drug in Healthy Adult Volunteers, Then in Adults with Ulcerative Colitis Recruiting
  2025-522702-21-00 4 2026-01-26 Ulcerative Colitis is a type of inflammatory bowel disease, a chronic
• A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting
  2024-520097-36-00 5 2026-01-07 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia Recruiting
  2025-521216-19-00 5 2025-12-10 Schizophrenia
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting
  2025-520746-30-00 5 2025-11-18 Mild to moderate Alzheimer’s Disease
• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 5 2025-11-12 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
• A Phase III, Open-label, Single Arm, Prospective, Multicenter Study to Assess Efficacy and Safety of Kedrion Intravenous Human Normal Immuno … Recruiting
  2023-507115-35-00 5 2025-11-03 Chronic Immune Thrombocytopenia (ITP)
• A study to understand the safety and benefit of AlloNK® with rituximab in patients with hard-to-treat rheumatic diseases Recruiting
  2025-520461-41-00 4 2025-10-22 Systemic Sclerosis (SSc)
• Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects Recruiting
  2023-508804-39-00 5 2025-10-15 Ulcerative Colitis or Crohn’s Disease
• A Phase 3 Single-arm Study of UGN-104 for the Treatment of LG-UTUC Recruiting
  2024-519343-15-00 5 2025-10-08 Low-grade Upper Tract Urothelial Cancer

Showing 49–72 of 653 trials